Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Viralytics Ltd Receives MHRA Approval For UK Clinical Trial


Tuesday, 10 Sep 2013 08:08pm EDT 

Viralytics Ltd announced that it has received final approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to undertake the Phase I/II clinical trial of CAVATAK in cancer patients. The approved study will assess the multiple intravenous (systemic) delivery of CAVATAK in patients with late stage melanoma, prostate, lung or metastatic bladder cancers. This trial, referred to as the STORM (Systemic Treatment Of Resistant Malignancies) study will be undertaken at three prestigious cancer centres in the UK. The lead study investigators are prominent oncologists Professor Hardev Pandha (The University of Surrey), Professor Kevin Harrington (The Institute of Cancer Research and The Royal Marsden, London) and Professor Alan Melcher (St James's University Hospital, Leeds). In the first stage of the STORM study, CAVATAK will be administered as a monotherapy in late stage cancer patients. In the second stage, CAVATAK will be administered in conjunction with docetaxel or carboplatin/paclitaxel targeting only one cancer type. That cancer type will be identified as the most promising target from the first stage of the study. 

Company Quote

0.275
0.0050 +1.85%
16 Sep 2014